Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

September 2012

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Active disease in chronic hepatitis C patients with normal alanine aminotransferase. Arif A, Ahmed W, Alam SE, Qureshi H. J Coll Physicians Surg Pak. 2012 Aug;22(8):488-91.

http://www.ncbi.nlm.nih.gov/pubmed/22868012

 

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eskesen AN, Melum E, Moghaddam A, et al.. Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6.

http://www.ncbi.nlm.nih.gov/pubmed/22584257

 

Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial. Furusyo N, Ogawa E, Sudoh M, et al. J Hepatol. 2012 Aug 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22889955

 

The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B. Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):1013-6.

http://www.ncbi.nlm.nih.gov/pubmed/22913149

 

RANTES, TNF-α, Oxidative Stress, and Hematological Abnormalities in Hepatitis C Virus Infection. Tawadrous GA, Aziz AA, Amin DG, Eldemery A, Mostafa MA. J Investig Med. 2012 Aug;60(6):878-82.

http://www.ncbi.nlm.nih.gov/pubmed/22534629

 

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? Papastergiou V, Dimitroulopoulos D, Skorda L, et al. J Med Virol. 2012 Aug;84(8):1217-23. doi: 10.1002/jmv.23324.

http://www.ncbi.nlm.nih.gov/pubmed/22711349

 

Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus. El-Kamary SS, Hashem M, Saleh DA, et al. J Pediatr. 2012 Aug 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22883419

 

Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. Amanzada A, Schneider S, Moriconi F, et al. J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.

http://www.ncbi.nlm.nih.gov/pubmed/22711348

 

Basic and Applied Science, Pre-Clinical Studies

 

Induction of microRNA-214-5p in human and rodent liver fibrosis. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, Kawada N. Fibrogenesis Tissue Repair. 2012 Aug 1;5(1):12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22849305

 

Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and ent1(-/-) mice. Moss AM, Endres CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Mol Pharm. 2012 Sep 4;9(9):2442-9. Epub 2012 Aug 3.

http://www.ncbi.nlm.nih.gov/pubmed/22812541

 

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Yano Y, Seo Y, Miki A, et al. Int J Mol Med. 2012 Aug 9. doi: 10.3892/ijmm.2012.1093. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22899224

 

Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells. Alisi A, Arciello M, Petrini S, Conti B, Missale G, Balsano C. PLoS One. 2012;7(8):e44147. Epub 2012 Aug 28.

http://www.ncbi.nlm.nih.gov/pubmed/22937161

 

Hepatitis C virus translation preferentially depends on active RNA replication. Liu HM, Aizaki H, Machida K, Ou JH, Lai MM. PLoS One. 2012;7(8):e43600. Epub 2012 Aug 24.

http://www.ncbi.nlm.nih.gov/pubmed/22937067

 

Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. Morin TJ, Broering TJ, Leav BA, et al. PLoS Pathog. 2012 Aug;8(8):e1002895. Epub 2012 Aug 30.

http://www.ncbi.nlm.nih.gov/pubmed/22952447

 

Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. Ribeiro RM, Li H, Wang S, et al. PLoS Pathog. 2012 Aug;8(8):e1002881. Epub 2012 Aug 23.

http://www.ncbi.nlm.nih.gov/pubmed/22927817

 

Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. Li H, Stoddard MB, Wang S, et al. PLoS Pathog. 2012 Aug;8(8):e1002880. Epub 2012 Aug 23.

http://www.ncbi.nlm.nih.gov/pubmed/22927816

 

Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly. Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. PLoS Pathog. 2012 Aug;8(8):e1002845. Epub 2012 Aug 16.

http://www.ncbi.nlm.nih.gov/pubmed/22916011

 

Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis. Hirata Y, Ikeda K, Sudoh M, et al. PLoS Pathog. 2012 Aug;8(8):e1002860. Epub 2012 Aug 16.

http://www.ncbi.nlm.nih.gov/pubmed/22916015

 

Comparison of Hepatitis C virus subtyping by ns5b sequencing with 5'utr based methods.

Pagani E, Huemer HP, Pasquetto V, Cemin C, Molon L, Rossi P, Larcher C. Minerva Med. 2012 Aug;103(4):293-7.

http://www.ncbi.nlm.nih.gov/pubmed/22805621

 

Patient-Derived Hepatitis C Virus and HCV JFH-1 Clones Differ in Their Ability to Infect Human Hepatoma Cells and Lymphocytes. Sarhan MA, Chen AY, Russell RS, Michalak TI. J Gen Virol. 2012 Aug 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22855787

 

HIV/HCV Coinfection

 

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. Mira JA, Rivero A, de Los Santos-Gil I, et al. AIDS. 2012 Aug 24;26(13):1721-1724.

http://www.ncbi.nlm.nih.gov/pubmed/22695304

 

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. Grebely J, Hellard M, Applegate T, et al. AIDS. 2012 Aug 24;26(13):1653-1661.

http://www.ncbi.nlm.nih.gov/pubmed/22555168

 

Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ, Naggie S. AIDS Patient Care STDS. 2012 Sep;26(9):541-5. Epub 2012 Aug 3.

http://www.ncbi.nlm.nih.gov/pubmed/22860997

 

Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic.

Wandeler G, Gsponer T, Bregenzer A, et al. Clin Infect Dis. 2012 Aug 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22893583

 

Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal amino-transferases levels. Pace FH, Ferreira LE, Silva AE, Ferraz ML. Rev Soc Bras Med Trop. 2012 Aug;45(4):444-7.

http://www.ncbi.nlm.nih.gov/pubmed/22930041

 

Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J. Antiviral Res. 2012 Aug;95(2):72-81. Epub 2012 Jun 7.

http://www.ncbi.nlm.nih.gov/pubmed/22683884

 

Complementary and Alternative Medicine

 

Evidence That Naturopathic Therapy Including Cordyceps sinensis Prolongs Survival of Patients With Hepatocellular Carcinoma. Niwa Y, Matsuura H, Murakami M, Sato J, Hirai K, Sumi H. Integr Cancer Ther. 2012 Aug 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22544231

 

Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, Chen JC, Liu YW. Int J Mol Med. 2012 Aug 20. doi: 10.3892/ijmm.2012.1096. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22922731

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32.

http://www.ncbi.nlm.nih.gov/pubmed/22895429

 

Prevalence and correlates of HIV and HCV infection among amphetamine-type stimulant users in 6 provinces in China. Bao YP, Liu ZM, Lian Z, et al. J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):438-46.

http://www.ncbi.nlm.nih.gov/pubmed/22481605

 

Syringe Acquisition Experiences and Attitudes among Injection Drug Users Undergoing Short-Term Opioid Detoxification in Massachusetts and Rhode Island. Zaller ND, Yokell MA, Nayak SM, Fu JJ, Bazazi AR, Rich JD. J Urban Health. 2012 Aug;89(4):659-70.

http://www.ncbi.nlm.nih.gov/pubmed/22427232

 

Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. Spradling PR, Rupp L, Moorman AC, et al. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22875876

 

Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. Chen SH, Li YF, Lai HC, et al. BMC Gastroenterol. 2012 Aug 10;12(1):105. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22877310

 

Liver Cancer

 

From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression. Wang Y, Li J, Chen J, Liu L, Peng Z, Ding J, Ding K. Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):995-1000.

http://www.ncbi.nlm.nih.gov/pubmed/22913147

 

Causes of and prevention strategies for hepatocellular carcinoma. Cabibbo G, Maida M, Genco C, Antonucci M, Camm C. Semin Oncol. 2012 Aug;39(4):374-83.

http://www.ncbi.nlm.nih.gov/pubmed/22846856

 

An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer. Momin B, Richardson L. J Community Health. 2012 Aug;37(4):912-6.

http://www.ncbi.nlm.nih.gov/pubmed/22160788

 

Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. Takeyasu M, Akuta N, Suzuki F, et al. J Med Virol. 2012 Aug;84(8):1199-207. doi: 10.1002/jmv.23288.

http://www.ncbi.nlm.nih.gov/pubmed/22711347

 

An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens. Hakre S, Upshaw-Combs DR, Sanders-Buell EE, et al. Mil Med. 2012 Aug;177(8):930-8.

http://www.ncbi.nlm.nih.gov/pubmed/22934373

 

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Izumi N, Asahina Y, Kurosaki M, et al. J Gastroenterol. 2012 Aug 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22875473

 

Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.

Kuske L, Mensen A, M Llhaupt B, et al. Swiss Med Wkly. 2012 Aug 6;142:0. doi: 10.4414/smw.2012.13651.

http://www.ncbi.nlm.nih.gov/pubmed/22869395

 

Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma. Soyemi OM Dr, Otegbayo JA Dr, Ola SO Dr, Akere A Dr, Soyemi T Dr. BMC Res Notes. 2012 Aug 3;5(1):403. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22856336

 

Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Hepatology. 2012 Sep;56(3):994-1003. doi: 10.1002/hep.25706. Epub 2012 Aug 2.

http://www.ncbi.nlm.nih.gov/pubmed/22407776

 

A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. Hernandez-Alejandro R, Croome KP, Drage M, et al. World J Gastroenterol. 2012 Aug 21;18(31):4145-9.

http://www.ncbi.nlm.nih.gov/pubmed/22919246

 

Incidence of Hepatocellular Carcinoma among US Patients with Cirrhosis of Viral or Non-Viral Etiologies. Mair RD, Valenzuela A, Ha NB, et al. Clin Gastroenterol Hepatol. 2012 Aug 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22902757